Molecular Cancer Therapeutics CTRC-AACR San Antonio Breast Cancer Symposium Targeting the PI3-Kinase Pathway in Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gibson, P.
Right arrow Articles by Loadman, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gibson, P.
Right arrow Articles by Loadman, P. M.
Vol. 2, 527-534, June 2003     Molecular Cancer Therapeutics
© 2003 American Association for Cancer Research

Cytochrome P450 1B1 (CYP1B1) Is Overexpressed in Human Colon Adenocarcinomas Relative to Normal Colon: Implications for Drug Development1

Paul Gibson, Jason H. Gill, Parveen A. Khan, Jill M. Seargent, Sandie W. Martin, Philip A. Batman, John Griffith, Christopher Bradley, John A. Double, Michael C. Bibby and Paul M. Loadman2

Cancer Research UK Laboratories, Tom Connors Cancer Research Centre, University of Bradford, Bradford BD7 1DP [P. G., J. H. G., P. A. K., J. M. S., S. W. M., M. C. B., J. A. D., P. M. L.], and Departments of Histopathology [P. A. B.], General Surgery [J. G.], and Oncology [C. B.], Bradford Royal Infirmary, Bradford BD9 6RJ, United Kingdom

2 To whom requests for reprints should be addressed, at Cancer Research UK Laboratories, Tom Connors Cancer Research Centre, University of Bradford, Bradford BD7 1DP, United Kingdom. Phone: 44-0-1274-233228; Fax: 44-0-1274-233234; E-mail: p.m.loadman{at}bradford.ac.uk

The cytochrome P450 family of enzymes is involved in the Phase I metabolism of a wide variety of compounds. Although generally involved with detoxification, overexpression of one family member, cytochrome P450 1B1 (CYP1B1), has been associated with human epithelial tumors. As such, CYP1B1 was hypothesized to be a novel target for the development of anticancer therapies. We investigated expression of CYP1B1 protein in 61 human colorectal adenocarcinomas and compared this to that observed in 14 histologically normal human large bowel samples removed from patients undergoing surgery for large bowel tumors. Although we confirmed that CYP1B1 was expressed at high levels in human colorectal tumor epithelia, we also found that CYP1B1 was not absent from normal colonic epithelia but was expressed at low levels. The expression of CYP1B1 in colon tumors does not correlate with tumor stage or degree of lymph node invasion in this study. Furthermore, in addition to expression in colon epithelia, CYP1B1 is also observed in blood vessels within the colon. As with the epithelia, levels of CYP1B1 were higher in tumor vasculature than that of the normal colon. Although these observations greatly support the development of CYP1B1 targeted anticancer therapies, they also indicate the caution that should be observed when developing such drugs.




This article has been cited by other articles:


Home page
MutagenesisHome page
R. M. Green, N. J. Hodges, J. K. Chipman, M. R. O'Donovan, and M. Graham
Reactive oxygen species from the uncoupling of human cytochrome P450 1B1 may contribute to the carcinogenicity of dioxin-like polychlorinated biphenyls
Mutagenesis, June 26, 2008; (2008) gen035v1.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
T. M. Sissung, D. K. Price, A. Sparreboom, and W. D. Figg
Pharmacogenetics and Regulation of Human Cytochrome P450 1B1: Implications in Hormone-Mediated Tumor Metabolism and a Novel Target for Therapeutic Intervention
Mol. Cancer Res., March 1, 2006; 4(3): 135 - 150.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Tokizane, H. Shiina, M. Igawa, H. Enokida, S. Urakami, T. Kawakami, T. Ogishima, S. T. Okino, L.-C. Li, Y. Tanaka, et al.
Cytochrome P450 1B1 Is Overexpressed and Regulated by Hypomethylation in Prostate Cancer
Clin. Cancer Res., August 15, 2005; 11(16): 5793 - 5801.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Kumarakulasingham, P. H. Rooney, S. R. Dundas, C. Telfer, W. T. Melvin, S. Curran, and G. I. Murray
Cytochrome P450 Profile of Colorectal Cancer: Identification of Markers of Prognosis
Clin. Cancer Res., May 15, 2005; 11(10): 3758 - 3765.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
J. L. Port, K. Yamaguchi, B. Du, M. De Lorenzo, M. Chang, P. M. Heerdt, L. Kopelovich, C. B. Marcus, N. K. Altorki, K. Subbaramaiah, et al.
Tobacco smoke induces CYP1B1 in the aerodigestive tract
Carcinogenesis, November 1, 2004; 25(11): 2275 - 2281.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
M. C. E. McFadyen, W. T. Melvin, and G. I. Murray
Cytochrome P450 enzymes: Novel options for cancer therapeutics
Mol. Cancer Ther., March 1, 2004; 3(3): 363 - 371.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.